Presight Capital is the flagship venture capital fund of Apeiron Investement Group and invests across sectors in the most ambitious founders worldwide, from seed to growth stages.
Our mission isto be steadfast andcommitted to outlierentrepreneurs.
We are a full lifecycle investor and write tickets in the range of 500K to $20M and from seed to growth stages.
Our JourneySince 2019
$600M+
Assets Under Management
+50
Portfolio
Companies
8+
Sectors Invested In
6+
Portfolio Public Listings
3+
Unicorns Backed
Presight is
a multi-sector,
full-lifecycle
investor.
Our featured
companies
AbCellera focuses on the discovery and development process of antibody drugs, the largest and fastest growing class of successful biologic therapeutics.
Atai is a Nasdaq listed clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. We also invested early in Nasdaq listed Compass Pathways, a subsidiary of ATAI, which is developing psilocybin therapy to help people with treatment-resistant depression.
General Fusion is a clean energy company developing the first commercially-viable fusion power plant.
News
Read
Berlin’s Razor Group raises $125M at a $1B+ valuation
In the latest development, Berlin’s Razor Group has now raised $125 million of equity funding in a Series B round that CEO and co-founder Tushar Ahluwalia said pushes the company past a $1 billion valuation.
Read
UpScalio raises $42.5 million in funding
A consortium of lenders, including freshly minted unicorn OfBusiness, Innoven Capital, and Alteria Capital, have also committed capital to the platform.
Read
International VC firm Presight Capital raises $350M second fund
Presight Capital has closed its $350 million second fund only a year and a half after it announced an $80 million first fund.